Physician profile
Alan D Furst
NPI 1164459962
$2,636.32
in general payments reported to CMS, 2019-2025
29 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $50.35 · 2021: $255 · 2022: $474 · 2023: $560 · 2024: $706 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $629.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $602.92 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $250.62 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $180.50 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $150.86 | 2022-2025 | |
| Lilly USA, LLC | $93.99 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $84.63 | 2019-2023 | Shingrix |
| Axsome Therapeutics, INC. | $77.22 | 2023-2024 | Auvelity |
| Amgen INC. | $65.97 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.27 | 2023-2025 | Trintellix |
| Astellas Pharma US INC | $62.77 | 2023-2025 | Veozah |
| Ibsa Pharma INC. | $56.08 | 2023-2024 | Tirosint, Licart, Tirosint |
| Amarin Pharma, INC. | $42.03 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $33.80 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $28.34 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $22.83 | 2019-2020 | |
| Abbott Laboratories | $22.51 | 2023 | Freestyle Libre 2 |
| Corium, LLC | $19.67 | 2024 | Azstarys |
| Paratek Pharmaceuticals, INC. | $16.96 | 2024 | Nuzyra |
| Janssen Pharmaceuticals, INC | $16.19 | 2024 | Spravato |
| Dexcom, INC. | $16.10 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.07 | 2025 | Rexulti |
| Seqirus USA INC | $14.99 | 2024 | Fluad, Flucelvax |
| Biohaven Pharmaceutical Holding Company LTD. | $14.29 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.58 | 2019 | |
| Neos Therapeutics, LP | $12.64 | 2019 | |
| Sanofi Pasteur INC. | $12.00 | 2019 | |
| Aytu Biopharma, INC. | $11.19 | 2020 | |
| Althera Pharmaceuticals LLC | $4.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Furst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.